Valneva (VALN) said Monday that France's national public health agency suspended the use of single-dose chikungunya vaccine Ixchiq in persons at least 65 years old after three cases of serious adverse events, including one death.
The company said "causality has not been definitively established" and the suspension will remain in place pending further investigation.
The serious adverse events, which were reported through the country's pharmacovigilance system, involved individuals over 80 years old with comorbidities who received the vaccine, according to the company.
The vaccine is still recommended for use in individuals 18 to 64 years old in France, Valneva said.
Shares of Valneva were down 7.6% in recent trading.
Price: 6.53, Change: -0.54, Percent Change: -7.64
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。